Oseltamivir
Oseltamivir is an antiviral agent reduces replication of influenza A and B viruses by inhibiting viral neuraminidase. Oseltamivir is most effective for the treatment of influenza if started within a few hours of the onset of the symptoms. Oseltamivir is also used for the prophylaxis when used within 48 hours of exposure to influenza.
Primary Characteristics
Molecular Weight: 410.4 · Non-proprietary name: Oseltamivir.
Pharmacokinetics
Absorption: Oseltamivir has an oral bioavailability is 79% (±12%), pre-systemic (first-pass) metabolism accounts for 73% (±2%).
Distribution: Oseltamivir has a volume of distribution is 0.37(0.28-0.46)l/kg. plasma protein binding is about 3%.
Elimination: plasma half-life is 1.8(0.6-3)%, renal excretion is 93(72-114)%.
Advertisement
Indications
Oseltamivir is primarily indicated in conditions like Acid-related dyspepsia, Influenza prophylaxis, Prevention of influenza, Treatment of influenza.
Contraindications
None recorded.
Dosage
Oseltamivir's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 75 mg | 75 mg | Every 2h | PO | For 5 days start dose with in 48 hrs |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Oseltamivir produces potentially life-threatening effects which include Asthma , Bronchitis. Careful monitoring is needed with proper medical management.
Oseltamivir is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Conjunctivitis, Dermatitis, Diarrhea, Dizziness, Ear disorders, Fatigue, Headache, Insomnia, Nausea and vomiting, Pheumonia, Rashes .
Warnings / Precautions
Interference in Pathology
Oseltamivir may interfere in the diagnosis of Liver Function Test (LFT) .
Available Brands
Click on a strength to view available brands.
Single Ingredient
Drug Classification
- 1.6.5.3
- 2.6.5.3